Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


What Moved Markets This Week

2026-02-07
Weekly stock market update: Dow hits 50,000 as tech sells off; Bitcoin volatility, jobs data and top stock calls.

IQVIA Q4 Earnings Call Highlights

2026-02-07
IQVIA (NYSE:IQV) executives said the company closed 2025 with a “strong” fourth quarter as revenue came in above the high end of management’s guidance range and clinical demand indicators improved as the year progressed. On the company’s fourth-quarter earnings call, management also introduced a sim

IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis

2026-02-06
Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.

IQVIA Holdings Inc (IQV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

2026-02-05
IQVIA Holdings Inc (IQV) reports robust fourth-quarter performance with a 10.3% revenue increase and strategic advancements in AI and cloud technologies.

IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y

2026-02-05
IQV posted a fourth-quarter 2025 earnings and revenue beat with double-digit Y/Y sales growth, strong segment gains and upbeat 2026 revenue guidance.

IQVIA (IQV) Stock Trades Down, Here Is Why

2026-02-05
Shares of clinical research company IQVIA (NYSE: IQV) fell 8.5% in the morning session after the company issued a weak full-year 2026 profit forecast that fell below Wall Street expectations.

IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript

2026-02-05

IQVIA Holdings Inc. 2025 Q4 - Results - Earnings Call Presentation

2026-02-05
2026-02-05. The following slide deck was published by IQVIA Holdings Inc.

IQVIA forecasts weak annual profit on higher interest expenses

2026-02-05
Feb 5 (Reuters) - Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong

IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates

2026-02-05
IQVIA (IQV) delivered earnings and revenue surprises of +0.50% and +2.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?